<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03909763</url>
  </required_header>
  <id_info>
    <org_study_id>ZXH81470343</org_study_id>
    <nct_id>NCT03909763</nct_id>
  </id_info>
  <brief_title>Combination of Danazole With Berberine in the Treatment of ITP</brief_title>
  <official_title>Combination of Danazole With Berberine in the Treatment of ITP</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking University People's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Peking University People's Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A prospective, multicenter, open-label, Phase II, single arm, trial performed in 6&#xD;
      departments of hematology in China&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Immune thrombocytopenia (ITP) is an autoimmune disorder characterized by low platelet count&#xD;
      and mucocutaneous bleeding. Approximately one-third of ITP patients fail to respond to&#xD;
      first-line therapies. In addition, a certain amount of the patients relapse and require&#xD;
      further therapy after one or more treatment strategies (e.g., thrombopoietin receptor&#xD;
      agonists or rituximab). The optimal second-line treatment remains a challenge.Berberine&#xD;
      (BBR), an isoquinoline alkaloid derived from plants, is widely used as a nonprescription drug&#xD;
      to treat diarrhea. Our previous data demonstrated that gut microbiota dysbiosis may&#xD;
      contribute to the development of corticosteroid-resistant ITP. BBR may correct&#xD;
      corticosteroid-resistance by modulating the gut microbiota structure, thus being a novel&#xD;
      potential second-line candidate to treat ITP. Importantly, the potential clinical benefits of&#xD;
      BBR have already been evaluated in various studies using human subjects, and it has been&#xD;
      shown to be safe. Danazol is an attenuated androgen that has successfully been used in the&#xD;
      treatment of ITP. Considering the side-effects of a regular dose of danazol and that BBR and&#xD;
      danazol share disparate mechanisms in the treatment of ITP, we hypothesized that the&#xD;
      combination of these two agents might be a promising option to maximize efficacy while&#xD;
      minimizing adverse effects. Therefore, we aimed to evaluate the long-term efficacy and safety&#xD;
      of berberine plus danazol in patients with corticosteroid-resistant or relapsed ITP.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">January 20, 2016</start_date>
  <completion_date type="Anticipated">June 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Count of Participants That Achieved 6-month Sustained Response</measure>
    <time_frame>6 month</time_frame>
    <description>6-month sustained response defined as platelet count of 30×10⁹/L or more and at least a doubling of baseline platelet count (partial response (PR)), or a platelet count of 100×10⁹/L or more and the absence of bleeding without rescue medication(complete response (CR))</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>the Count of Participants That Had Adverse Events</measure>
    <time_frame>2 years</time_frame>
    <description>any adverse events/serious adverse events associated with study drugs and bleeding events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the Count of Participants That Achieved Initial Response</measure>
    <time_frame>4 weeks</time_frame>
    <description>Initial response by day 28. Initial response includes partial response (PLT of 30×10⁹/L or more and at least a doubling of baseline platelet count) and complete response (PLT of 100×10⁹/L or more and the absence of bleeding without rescue medication).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DOR</measure>
    <time_frame>2 years</time_frame>
    <description>duration of response (DOR)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">55</enrollment>
  <condition>Corticosteroid-resistant or Relapsed ITP</condition>
  <arm_group>
    <arm_group_label>Berberine plus danazol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Berberine plus danazol group</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Berberine plus danazol</intervention_name>
    <description>Oral BBR (0.3g thrice daily) plus oral danazol (200 mg twice daily) for 16 weeks</description>
    <arm_group_label>Berberine plus danazol</arm_group_label>
    <other_name>HangZhou Mingsheng of China</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Clinically confirmed immune thrombocytopenic purpura (ITP) newly diagnosed&#xD;
&#xD;
          2. Platelet count less than 30×109/L on two occasions or Platelets above 30×109/L&#xD;
             combined with bleeding manifestation&#xD;
&#xD;
          3. Subject is ≥ 18 years and ≤80years&#xD;
&#xD;
          4. Subject has signed and dated written informed consent.&#xD;
&#xD;
          5. Fertile patients must use effective contraception during treatment and observational&#xD;
             period&#xD;
&#xD;
          6. Negative pregnancy test&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Have an impaired renal function as indicated by a serum creatinine level &gt; 2.0 mg/dL&#xD;
&#xD;
          2. Have an inadequate liver function as indicated by a total bilirubin level &gt; 2.0 mg/dL&#xD;
             and/or an aspartate aminotransaminase or alanine aminotransferase level &gt; 3×upper&#xD;
             limit of normal&#xD;
&#xD;
          3. Have a New York Heart Classification III or IV heart disease&#xD;
&#xD;
          4. Have a history of severe psychiatric disorder or are unable to comply with study and&#xD;
             follow-up procedures&#xD;
&#xD;
          5. Have active hepatitis B or hepatitis C infection&#xD;
&#xD;
          6. Have a HIV infection&#xD;
&#xD;
          7. Have active infection requiring antibiotic therapy within 7 days prior to study entry&#xD;
&#xD;
          8. Are pregnant or lactating women, or plan to become pregnant or impregnated within 12&#xD;
             months of receiving study drug&#xD;
&#xD;
          9. Previous treatment with rituximab&#xD;
&#xD;
         10. Previous splenectomy&#xD;
&#xD;
         11. Had previous or concomitant malignant disease&#xD;
&#xD;
         12. Not willing to participate in the study.&#xD;
&#xD;
         13. Expected survival of &lt; 2 years&#xD;
&#xD;
         14. Intolerant to murine antibodies&#xD;
&#xD;
         15. Immunosuppressive treatment within the last month&#xD;
&#xD;
         16. Connective tissue disease&#xD;
&#xD;
         17. Autoimmune hemolytic anemia&#xD;
&#xD;
         18. Patients currently involved in another clinical trial with evaluation of drug&#xD;
             treatment&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xiaohui Zhang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Peking University of people's hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Peking University Institute of Hematology</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100044</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>April 8, 2019</study_first_submitted>
  <study_first_submitted_qc>April 8, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 10, 2019</study_first_posted>
  <results_first_submitted>August 3, 2020</results_first_submitted>
  <results_first_submitted_qc>September 4, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">September 25, 2020</results_first_posted>
  <last_update_submitted>September 4, 2020</last_update_submitted>
  <last_update_submitted_qc>September 4, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 25, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Peking University People's Hospital</investigator_affiliation>
    <investigator_full_name>Xiao Hui Zhang</investigator_full_name>
    <investigator_title>Prof.</investigator_title>
  </responsible_party>
  <keyword>corticosteroid-resistant or relapsed ITP</keyword>
  <keyword>Danazole</keyword>
  <keyword>berberine</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Danazol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>January 1, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/63/NCT03909763/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Berberine Plus Danazol</title>
          <description>Berberine plus danazol group&#xD;
Berberine plus danazol: Oral BBR (0.3g thrice daily) plus oral danazol (200 mg twice daily) for 16 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="55"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="45"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Berberine Plus Danazol</title>
          <description>Berberine plus danazol group&#xD;
Berberine plus danazol: Oral BBR (0.3g thrice daily) plus oral danazol (200 mg twice daily) for 16 weeks</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="45"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="45"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45" lower_limit="18" upper_limit="67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="45"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Count of Participants That Achieved 6-month Sustained Response</title>
        <description>6-month sustained response defined as platelet count of 30×10⁹/L or more and at least a doubling of baseline platelet count (partial response (PR)), or a platelet count of 100×10⁹/L or more and the absence of bleeding without rescue medication(complete response (CR))</description>
        <time_frame>6 month</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Berberine Plus Danazol</title>
            <description>Berberine plus danazol group&#xD;
Berberine plus danazol: Oral BBR (0.3g thrice daily) plus oral danazol (200 mg twice daily) for 16 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>The Count of Participants That Achieved 6-month Sustained Response</title>
          <description>6-month sustained response defined as platelet count of 30×10⁹/L or more and at least a doubling of baseline platelet count (partial response (PR)), or a platelet count of 100×10⁹/L or more and the absence of bleeding without rescue medication(complete response (CR))</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>the Count of Participants That Had Adverse Events</title>
        <description>any adverse events/serious adverse events associated with study drugs and bleeding events</description>
        <time_frame>2 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Berberine Plus Danazol</title>
            <description>Berberine plus danazol group&#xD;
Berberine plus danazol: Oral BBR (0.3g thrice daily) plus oral danazol (200 mg twice daily) for 16 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>the Count of Participants That Had Adverse Events</title>
          <description>any adverse events/serious adverse events associated with study drugs and bleeding events</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Adverse events associated with study drugs</title>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Bleeding events</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No adverse events</title>
                  <measurement_list>
                    <measurement group_id="O1" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>the Count of Participants That Achieved Initial Response</title>
        <description>Initial response by day 28. Initial response includes partial response (PLT of 30×10⁹/L or more and at least a doubling of baseline platelet count) and complete response (PLT of 100×10⁹/L or more and the absence of bleeding without rescue medication).</description>
        <time_frame>4 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Berberine Plus Danazol</title>
            <description>Berberine plus danazol group&#xD;
Berberine plus danazol: Oral BBR (0.3g thrice daily) plus oral danazol (200 mg twice daily) for 16 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>the Count of Participants That Achieved Initial Response</title>
          <description>Initial response by day 28. Initial response includes partial response (PLT of 30×10⁹/L or more and at least a doubling of baseline platelet count) and complete response (PLT of 100×10⁹/L or more and the absence of bleeding without rescue medication).</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>DOR</title>
        <description>duration of response (DOR)</description>
        <time_frame>2 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Berberine Plus Danazol</title>
            <description>Berberine plus danazol group&#xD;
Berberine plus danazol: Oral BBR (0.3g thrice daily) plus oral danazol (200 mg twice daily) for 16 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>DOR</title>
          <description>duration of response (DOR)</description>
          <units>months</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.2" spread="10.731"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>2 years</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Berberine Plus Danazol</title>
          <description>Berberine plus danazol group&#xD;
Berberine plus danazol: Oral BBR (0.3g thrice daily) plus oral danazol (200 mg twice daily) for 16 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Intracranial bleeding</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>seborrheic dermatitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>androgenetic alopecia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Xiaohui Zhang, Director of Clinical Trials</name_or_title>
      <organization>Peking University People's Hospital</organization>
      <phone>86-10-88324577</phone>
      <email>zhangxh@bjmu.edu.cn</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

